Navigation Links
Cylex Announces Brad L. Stewart as President of the Company
Date:4/8/2008

Mr. Stewart brings critical experience in strategic and operational

leadership to support expansion of the Company's current and future

opportunities

COLUMBIA, Md., April 8, 2008 /PRNewswire/ -- Cylex(TM) has announced the appointment of Brad L. Stewart as President of the Company. Cylex is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology to assay cell-mediated immunity (CMI).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080408/NETU096 )

"A major priority for Cylex has been the recruitment of an experienced leader who could bring greater focus to the company and convert our extraordinary patented technology assets into profitable product opportunities," said Seth Rudnick, MD, General Partner in Canaan VII (a Canaan Partners fund), a major investor in Cylex, in announcing Mr. Stewart's appointment. "We believe Brad is the individual who brings us that skill set."

"I am delighted to have been given this opportunity to join Cylex and to focus first and foremost on ways to expand the awareness of our first marketed product, the ImmuKnow(R) assay, within and beyond the transplant community," says Mr. Stewart. "I have already had the chance to identify means to accelerate understanding of the value of this technology in specific therapeutic areas. We are also convinced that Cylex can rapidly expand ex-US use of ImmuKnow to support patient care in many other countries. This is an exciting challenge for me personally, and I will have the backing of a talented team of professionals at Cylex who, I know, are eager to work with me in achieving very specific goals."

Mr. Stewart brings extensive leadership experience in the life sciences industry -- with biotech, pharmaceutical, orphan drug, diagnostic and related healthcare companies. Among other accomplishments, he established a new US business for a European pharmaceutical company; drove the strategic restructuring of the North American business unit of a global pharmaceutical company; created an operational improvement business within a major diagnostics company; and developed and managed joint ventures, including a multi-million dollar joint-venture with one of the world's largest pharmaceutical companies.

At Cylex, he will have full responsibility for global commercial operations, corporate strategy and business development.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.


'/>"/>
SOURCE Cylex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
2. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
3. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
4. Martek Announces Final Judgment and Order of Dismissal in Class Action
5. Microbia Announces Name Change to Ironwood Pharmaceuticals
6. China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
7. Medicsight Announces New Marketing Partnership with INFINITT
8. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Cambridge Semantics , ... industry-leading provider in the Big Data special edition of CIOReview magazine. , Since ... into the latest technologies and solutions that are advancing the industry and optimizing ...
(Date:9/25/2017)... Korea (PRWEB) , ... September 25, 2017 , ... ... handheld computers, tablets and mobile payment devices, announced that they have been successfully ... (RNEC) in Colombia, which enables the commercial deployment in the region. , ...
(Date:9/25/2017)... (PRWEB) , ... September 25, ... ... industry-leading Unified Communications (UC) and Collaboration company, and Bigleaf Networks, the cloud-first ... a strategic alliance to extend CallTower’s Unified Communication applications with integrated Bigleaf ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... multiple case studies, presentations and demonstrations at SCDM 2017, held September 24-27, ... medical review teams and CRO partners for more automated capabilities across evolving ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):